Coherus Biosciences | CHRS - Loan Capital


Coherus Biosciences reported $51.08M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 24.75M 11.64M Jun/2026
ALKERMES USD 1.48B 7.23M Jun/2026
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Baxter International USD 8.62B 6M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 47.86B 8.49B Jun/2026
Fujifilm JPY 607.03B 35.21B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 51.08B 4.41B Jun/2026
Myriad Genetics USD 120.7M 400K Jun/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.28B 337.7M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Teva Pharmaceutical Industries USD 12.09B 1.92B Jun/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xencor USD 77.54M 4.59M Jun/2026
Zoetis USD 9.05B 3M Jun/2026